Effects of a Phenolic Ether, Su-13437, on Serum Cholesterol, Triglyceride, and Transaminase Levels of Human Subjects

Abstract

The hypolipidemic activity of the phenolic ether, 2-methyl-2-[p-(1,2,3,4-tetrahydro-1naphthyl)-phenoxy]-propionic acid (Su-13437, Ciba) has been studied in 10 hypercholesterolemic patients. The patients were studied at 3-week intervals during 30 weeks of placebo administration and a 30-week period of treatment with Su-13437, 400 mg daily.Individual mean serum total cholesterol during administration of placebo ranged from 255 to 609 mg/100 ml and during treatment from 187 to 493, the mean reduction being 22%. Five of the subjects were also hypertriglyceridemic, with individual mean levels of triglycerides during placebo periods ranging from 159 to 1247 mg/100 ml. During treatment with Su-13437 mean triglyceride levels of these five patients ranged from 81 to 314 mg/ 100 ml, a mean reduction of 51%.The drug was well tolerated and its only effect on the hematologic and biochemical tests for possible toxicity was an increase in SGOT and SGPT levels in two patients, the levels being maximal between the sixth and ninth weeks of drug administration and returning later toward pretreatment values despite continuation of Su-13437.

The hypolipidemic effect of SU‐13,437 in rats with natural endogenous hypertriglyceridemia

“…The prevalence of familial hyperlipoproteinemias (1)(2)(3)(4) as well as the direct relationship between hyperlipidemia and atherosclerosis in the human population (4-7) has indicated a need for blood lipid lowering compounds. The compound 2-methyl-2-[p- (1,2,3,4- man (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). However the study of this compound in experimental animals having abnormal lipid patterns has been limited.…”